Progesterone Receptor Negative Recruiting Phase 1 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02474173Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTreatment
NCT02672475Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerTreatment